January 31, 2014

Dr. Patricia Keegan
Director
Center for Drug evaluation and research
Food and Drug Administration
5901-B Ammendale Road
Beltsville, MD. 20707

Dear Dr. Keegan:

We write today on behalf of our friend Liza Cozad-Lauser, to urge that the Food and Drug Administration (FDA) allow her access to an experimental treatment she and her husband, David, believe is the only hope for saving her life.

We write to you together today not as fellow musicians, but as fellow Americans, hopeful that those entrusted with power and responsibility in our government will look with compassion and reason at the Lausers' request for access to this treatment.

As you know Liza has been diagnosed with inoperable cancer of the brain stem. She and David have requested that the FDA grant Liza access to an experimental treatment involving the use of antineoplastons (ANP).

We are aware there are differences of opinion within the medical community regarding the efficacy and potential of antineoplastons in treating patients afflicted with this illness. We are not asking for the FDA to take a side in this debate. We are writing to simply urge that Liza be allowed to receive the treatment she seeks while research on the potential of antineoplastons for potential widespread use continues.

There is no decision more personal than a decision about one's personal health, particularly when it involves matters of life and death. By insuring the medical products and procedures available to the public are safe—and insuring that patients and their families have access to as much information possible so they can make informed choices – government plays a valuable and vital role. But when government becomes a barrier to hope itself, it has exceeded its mandate. For Liza and David, the belief that the antineoplastons treatment could be effective is the flickering flame of hope that drives them in the battle against the cruel enemy that is cancer. The FDA has done its part in making them and other citizens aware of the pros and cons of this experimental treatment and the incomplete nature of the trials associated with it. Armed with that information,

and facing an illness that is otherwise known as incurable and fatal, Liza and David should be allowed to make the decision as to whether Liza will receive the treatment or not. The decision whether by decree or through inaction.
It is our understanding that physicians who are equipped and able to administer this treatment to Liza have notified her of their willingness to begin treating her immediately, on a pro bono basis.
We respectfully request that you grant Liza the access she seeks to this experimental treatment.

Sincerely,

Sammy Hagar

Joe Satriani

Michael Anthony (2-3-14)

Jack Blades

CC: Dr. Margaret A. Hamburg, Commissioner
U.S. Food and Drug Administration